TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30452784
Drug: Fulacimstat 10
Normalized name: Fulacimstat
DrugBank: Fulacimstat (DB15085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulacimstat 10 mg twice daily (n=9)
Study: 30452784
Drug: Fulacimstat 25
Normalized name: Fulacimstat
DrugBank: Fulacimstat (DB15085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulacimstat 25 mg twice daily (n=10)
Study: 30452784
Drug: Fulacimstat 50
Normalized name: Fulacimstat
DrugBank: Fulacimstat (DB15085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulacimstat 50 mg once daily (n=9)
Study: 27717303
Drug: Ribociclib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib (600 mg per day on a 3-weeks-on, 1-week-off schedule) plus letrozole (2.5 mg per day)
Study: 27717303
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus letrozole (2.5 mg per day)
Study: 20559229
Drug: Local cycloferon
Normalized name: Cicloferon
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local cycloferon liniment in comprehensive treatment of parodontitis
Study: 17589833
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER 225 mg
Study: 8784893
Drug: Intraosseous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraosseous injection with 1.8 ml of 2% lidocaine with 1:100,000 epinephrine
Study: 8784893
Drug: Intraosseous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraosseous injection
Study: 1461544
Drug: Nicardipine retard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine retard (40 mg twice a day)
Study: 1461544
Drug: Nicardipine retard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine retard + Hydrochlorothiazide (12.5 mg/day after 2 months if needed)
Study: 1461544
Drug: Captopril +
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril + Hydrochlorothiazide (12.5 mg/day after 2 months if needed)
Study: 6597708
Drug: Lidocaine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (40 mg, 2 ml of 2% lidocaine mixed with 50 ml of contrast medium)
Study: 31502003
Drug: Fibrinogen/Thrombin-Coated Collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen/Thrombin-Coated Collagen Patch (TachoSil®)
Study: 31502003
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no fibrin sealant patch)
Study: 29661389
Drug: Esketamine (cumulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine (cumulative dose 40 mg infused in 1 h)
Study: 26704011
Drug: Oral 500
Normalized name: OsCal 500 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 500 ml of 10% glucose solution two hours before surgery
Study: 26704011
Drug: Trial group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial group (Oral carbohydrate) vs Control group (Fasting)
Study: 24088271
Drug: IgM-enriched intravenous
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgM-enriched intravenous immunoglobulin (IVIG)
Study: 18444869
Drug: Switch arm
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch arm (half dose of stavudine)
Study: 18444869
Drug: Continuation arm
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation arm (standard dose of stavudine)
Study: 12657345
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg calcium supplement for 10 days
Study: 9052302
Drug: PCEA HM
Normalized name: DEXTRAN HM
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA HM 3‐mL (0.15 mg) bolus doses + saline 1 mL IV q6h (Group 1)
Study: 9052302
Drug: PCEA HM
Normalized name: DEXTRAN HM
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA HM (0.15 mg) in 0.125% bupivacaine 3‐mL bolus doses + saline 1 mL IV q6h (Group 2)
Study: 9052302
Drug: PCEA HM
Normalized name: DEXTRAN HM
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA HM 3‐mL (0.15 mg) bolus doses + ketorolac 1 mL (30 mg) IV q6h (Group 3)
Study: 27455158
Drug: Preoperative chemical
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemical thromboprophylaxis (CTP) with 5000 units of subcutaneous heparin
Study: 27455158
Drug: Postoperative chemical
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative chemical thromboprophylaxis (CTP) with 5000 units of subcutaneous heparin
Study: 25415813
Drug: PTNS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTNS plus tolterodine (4 mg daily for three months)
Study: 25415813
Drug: Tolterodine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine alone (4 mg daily for three months)
Study: 16622748
Drug: JTE‐522 (tiracoxib)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JTE‐522 (tiracoxib) 150 mg once daily for 26 weeks
Study: 16622748
Drug: JTE‐522 (tiracoxib)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JTE‐522 (tiracoxib) 200 mg once daily for 26 weeks
Study: 16622748
Drug: JTE‐522 (tiracoxib)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JTE‐522 (tiracoxib) 150 mg and 200 mg
Study: 8810935
Drug: Regular human
Normalized name: insulin regular human recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular human insulin 100 U mL‐1 (Actrapid) at a dose of 160 U
Study: 7917439
Drug: Information about
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information about symptoms of nicotine withdrawal, means of abstaining during hospitalization, means of permanently quitting, or medications for nicotine withdrawal symptoms.
Study: 2969315
Drug: cilazapril (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilazapril (mean dose 3.6 +/- 0.9 mg/day)
Study: 31185955
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (control A)
Study: 28320793
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg berryfruit polyphenolic extract (BFPE)
Study: 19583714
Drug: Vaginal repair
Normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal repair with mesh augmentation (mesh group, n = 69)
Study: 19583714
Drug: Vaginal repair
Normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal repair with mesh augmentation (mesh group)
Study: 9516068
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of systolic hypertension with calcium antagonists
Study: 1707109
Drug: Diltiazem (DZ)
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem (DZ) pretreatment and infusion (0.12 mg/kg/h for 74 hours starting 2 hours prior to surgery, continued with 90 mg b.i.d. p.o. until day 30)
Study: 290726
Drug: Propoxyphene napsylate
Normalized name: Propoxyphene Napsylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propoxyphene napsylate (50, 100, and 150 mg)
Study: 290726
Drug: Fenoprofen calcium
Normalized name: Fenoprofen Calcium
DrugBank: Fenoprofen (DB00573)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenoprofen calcium (200, 400, and 600 mg)
Study: 290726
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of propoxyphene (50/200, 100/400, and 150/600 mg)
Study: 31310960
Drug: Simulated amniotic
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulated amniotic fluid-like solution (SAFE)
Study: 26306733
Drug: Modified constraint-induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified constraint-induced movement therapy protocol (180 min of treatment/day for 10 days)
Study: 26306733
Drug: Modified constraint-induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified constraint-induced movement therapy protocol
Study: 22899425
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment for managing dysfunctional thoughts about caregiving and training in self-help techniques
Study: 12678210
Drug: Isoflavone supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone supplements
Study: 31183382
Drug: Traditional Karate
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional Karate (60 minutes twice a week for at least one year)
Study: 21684022
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy intervention (PTI)
Study: 20801187
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment in orchiectomised rats
Study: 16110692
Drug: Desmopressin 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin 0.05 mg
Study: 16110692
Drug: Desmopressin 0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin 0.10 mg
Study: 16110692
Drug: Desmopressin 0.15
Normalized name: desmopressin 0.15 mg/inh nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin 0.15 mg
Study: 16110692
Drug: Desmopressin 0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin 0.20 mg
Study: 12100776
Drug: Valdecoxib 10
Normalized name: valdecoxib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib 10 mg once daily
Study: 12100776
Drug: Valdecoxib 20
Normalized name: valdecoxib 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib 20 mg once daily
Study: 12100776
Drug: Valdecoxib 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib 5 mg once daily
Study: 7564369
Drug: moexipril 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: moexipril 3.75 mg o.d.
Study: 7564369
Drug: moexipril 7.5
Normalized name: moexipril 7.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: moexipril 7.5 mg o.d.
Study: 7564369
Drug: moexipril 15
Normalized name: moexipril 15 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: moexipril 15 mg o.d.
Study: 2187173
Drug: Neonatal screening
Normalized name: Foreskin fibroblast (neonatal)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neonatal screening using IRT cutoff of 180 ng/mL
Study: 6617280
Drug: heparin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: heparin and hydrocortisone
Study: 31462121
Drug: 595 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 595 nm pulsed-dye-laser (PDL) treatment (3 treatments, 10 mm spot size, 0.45 ms, 6 J/cm2)
Study: 24460536
Drug: Incentive-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incentive-based intervention including targeted education on myopia, structured weekend outdoor activities, and incentives for increasing daily steps via pedometers.
Study: 23278322
Drug: Diflubenzuron, Eprinomectin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflubenzuron, Eprinomectin, Fipronil, Ivermectin (feed-through treatments)
Study: 19888949
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (FCM) 15 mg/kg, maximum 1000 mg over 15 minutes
Study: 12852706
Drug: Glipizide/metformin 5/500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide/metformin 5/500 mg tablets
Study: 12852706
Drug: Glipizide 30
Normalized name: Glipizide
DrugBank: Glipizide (DB01067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glipizide 30 mg
Study: 12852706
Drug: Metformin 2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 2000 mg
Study: 10587555
Drug: Sclerosing injections
Normalized name: SCLEROSING AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sclerosing injections (dextrose-glycerine-phenol with lignocaine)
Study: 10587555
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections (saline plus lignocaine)
Study: 8945675
Drug: Sustained-release isosorbide-5-mononitrate
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release isosorbide-5-mononitrate
Study: 31564513
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg and Amlodipine 10 mg co-administration
Study: 31564513
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg alone
Study: 31564513
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of all 3 drugs
Study: 28142075
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day rosuvastatin (n = 24)
Study: 28142075
Drug: 80 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/day atorvastatin (n = 21)
Study: 28142075
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (LDL‐C <3.37 mmol/L)
Study: 27464953
Drug: Multimodal Rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal Rehabilitation Program (MRP) consisting of graded exposure module or a combination module of graded exposure and physical training, with a parent module added. Treatment duration varies between 7 and 16 weeks.
Study: 25124237
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine (three doses)
Study: 19678773
Drug: Verum acupuncture
Normalized name: Cinnamomum verum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verum acupuncture + 10 mg/day fluoxetine + placebo
Study: 19678773
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture + 20‐30 mg/day fluoxetine
Study: 11431189
Drug: Gabapentin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (200 to 300 mg after each hemodialysis session)
Study: 2783939
Drug: Interferon alfa-2a
Normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa-2a (3 million IU to 36 million IU intramuscularly daily for 10 weeks)
Study: 1097480
Drug: Protriptyline 10
Normalized name: protriptyline 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protriptyline 10 mg three times a day
Study: 1097480
Drug: Perphenazine 2
Normalized name: perphenazine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perphenazine 2 mg three times a day
Study: 1097480
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of protriptyline and perphenazine
Study: 25737169
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (lansoprazole, amoxicillin, and clarithromycin for 14 days)
Study: 25737169
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy plus probiotics (Lactobacillus casei, Lactobacillus acidophilus, and Bifidobacterium lactis)
Study: 21477426
Drug: Olopatadine 0.6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olopatadine 0.6% nasal spray (1 spray/nostril twice-daily)
Study: 21477426
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 spray/nostril twice-daily)
Study: 14626291
Drug: Hylan G‐F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hylan G‐F 20 (Synvisc®)
Study: 27349698
Drug: Edoxaban (higher-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban (higher-dose edoxaban regimen; 60 mg dose-reduced to 30 mg once daily)
Study: 22805873
Drug: Hypothermic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermic treatment (H)
Study: 22805873
Drug: Normothermic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normothermic treatment (N)
Study: 12569112
Drug: Konjac glucomannan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Konjac glucomannan (KGM) supplement (3.6 g/day) for 28 days
Study: 9139554
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of fluconazole per week
Study: 8229393
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid solution (4.8%) used as a mouthwash
Study: 3100353
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir 200 mg 4 times a day
Study: 30042362
Drug: Greek mountain
Normalized name: mountain pepper whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Greek mountain tea 950 mg
Study: 30042362
Drug: Greek mountain
Normalized name: mountain pepper whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Greek mountain tea 475 mg
Study: 30042362
Drug: Greek mountain
Normalized name: mountain pepper whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Greek mountain tea 475 mg and 950 mg
Study: 30042362
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba 240 mg
Study: 26760452
Drug: Scheduled SMS
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled SMS reminders (daily for 1 month, weekly for 2 months)
Study: 24951991
Drug: Microencapsulated fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microencapsulated fish oil (3 g/day containing 0.41 g/day of eicosapentaenoic acid and decosahexaneoic acid)
Study: 22313884
Drug: External methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: External methods of traditional Chinese medicine (TCM)
Study: 18717873
Drug: 5% doxepin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% doxepin hydrochloride cream
Study: 12798825
Drug: Beta-blockers (metoprolol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (metoprolol, bisoprolol, carvedilol)
Study: 12798825
Drug: Beta-blockers (CIBIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (CIBIS II trial)
Study: 10230185
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of atypical antipsychotics and psychosocial interventions
Study: 6310997
Drug: Amdinocillin plus
Normalized name: amdinocillin
DrugBank: Amdinocillin (DB01163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amdinocillin plus a beta-lactam antibiotic
Study: 6310997
Drug: Aminoglycoside plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoglycoside plus a beta-lactam antibiotic
Study: 27350625
Drug: Mirabegron (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron (160 mg once daily) with Metformin (500 mg twice daily)
Study: 27350625
Drug: Mirabegron (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron (100 mg once daily) with Warfarin (25 mg)
Study: 27350625
Drug: Mirabegron (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron (100 mg once daily) with Digoxin (0.25 mg)
Study: 27350625
Drug: Mirabegron (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron (100 mg once daily) with COC (30/150 µg once daily)
Study: 27350625
Drug: Mirabegron (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron (100 mg once daily)
Study: 26496210
Drug: 2 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 μg of paricalcitol
Study: 26496210
Drug: Treated groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treated groups (1 or 2 μg of paricalcitol)
Study: 24341367
Drug: FL‐PDT (Fractional
Approvals — FDA: no, EMA: no, PMDA: no
Description: FL‐PDT (Fractional laser-assisted photodynamic therapy)
Study: 24341367
Drug: MAL‐PDT (Methyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAL‐PDT (Methyl aminolevulinate photodynamic therapy)
Study: 19615128
Drug: Sequential non-invasive
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential non-invasive mechanical ventilation following short-term invasive mechanical ventilation
Study: 11489325
Drug: Reference immediate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference immediate release formulation
Study: 9430568
Drug: Morphine 2
Normalized name: apomorphine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 2 mg (Group A1)
Study: 9430568
Drug: Preoperative Morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative Morphine 2 mg (Group A2)
Study: 9430568
Drug: Morphine 5
Normalized name: ethylmorphine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 5 mg (Group A3)
Study: 9430568
Drug: Preoperative Morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative Morphine 5 mg (Group A4)
Study: 9430568
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% 20 ml (Group A5)
Study: 9430568
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% 20 ml + Morphine 2 mg (Group A6)
Study: 9430568
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution 20 ml (Group A7)
Study: 9430568
Drug: Morphine 5
Normalized name: ethylmorphine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 5 mg (Group B2)
Study: 9430568
Drug: Preoperative Morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative Morphine 5 mg (Group B3)
Study: 9430568
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% 20 ml + Morphine 2 mg (Group B5)
Study: 9430568
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution 20 ml (Control Group)
Study: 8512099
Drug: Intramuscular dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular dexmedetomidine (2.5 micrograms/kg) administered 60 min before induction (DEXPLA group, n = 64)
Study: 8512099
Drug: Intramuscular dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular dexmedetomidine (2.5 micrograms/kg) and intravenous fentanyl (1.5 micrograms/kg) (DEXFENT group, n = 64)
Study: 8512099
Drug: Intramuscular midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular midazolam (0.08 mg/kg) and intravenous fentanyl (1.5 micrograms/kg) (MIDFENT group, n = 64)
Study: 3582167
Drug: SADS-L
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SADS-L